In partnership with
🔬TODAY’S BREAKTHROUGH
A new study introduces a quantitative high-content screening system that can rapidly test thousands of compounds for their ability to block, induce, or clear senescent cells.
The Discovery:
Researchers built a reproducible workflow using fluorescence-based SA-β-gal detection and automated imaging to measure senescence in human fibroblasts. The system can calculate IC50/EC50 values for senescence modulators, enabling drug potency ranking. Screening 2,560 compounds revealed novel senolytics, senomorphics, and senescence inducers, validated through dose-response tests.
The Science:
Senescence induction: Mitomycin C reliably produced ~60% senescent cells in WI-38 fibroblasts.
Fluorescent imaging: SA-β-gal cleavage products were quantified by confocal imaging, aligning with manual counts.
Validation: Rapamycin reduced senescence markers (p16, p21, IL-6, CXCL1, HGF) with IC50 ~1.3 nM. Dasatinib + Quercetin and KU-60019 also tested.
Compound libraries: Screened 2,560 molecules (LOPAC + FDA-approved Prestwick library).
SenoScore metric: Combines SA-β-gal positivity and nuclear size for improved classification.
Hits: Identified new senolytics, senomorphics, and inducers; e.g., CPD-X004 acted as a senomorphic with effects on p16/p21 and confirmed IC50.
Applications: First system to quantify senescence drug potency and distinguish senolytics from senomorphics in high-throughput.
Your Action:
This is a lab breakthrough, not yet for clinical use. But it accelerates senotherapeutic discovery. For now, protect against senescence with proven habits: exercise, good sleep, nutrition, and avoiding toxins, all of which lower cellular stress.
Bottom Line:
A new automated platform makes senolytic drug discovery faster, more precise, and scalable.
Source:
An effective system for senescence modulating drug development using quantitative high-contesent analysis and high-throughput screening. Communications Biology. Hu Y, Xue X, Han T, Li Y, Zhang T, Lu T, Zhang P.
https://doi.org/10.1038/s42003-025-08758-6
How was today’s newsletter?
A Quick Favor:
We kindly ask you to check out the sponsor(s) that made this newsletter possible. Your support helps us continue sharing valuable insights and empowering your wellness journey.
How 433 Investors Unlocked 400X Return Potential
Institutional investors back startups to unlock outsized returns. Regular investors have to wait. But not anymore. Thanks to regulatory updates, some companies are doing things differently.
Take Revolut. In 2016, 433 regular people invested an average of $2,730. Today? They got a 400X buyout offer from the company, as Revolut’s valuation increased 89,900% in the same timeframe.
Founded by a former Zillow exec, Pacaso’s co-ownership tech reshapes the $1.3T vacation home market. They’ve earned $110M+ in gross profit to date, including 41% YoY growth in 2024 alone. They even reserved the Nasdaq ticker PCSO.
The same institutional investors behind Uber, Venmo, and eBay backed Pacaso. And you can join them. But not for long. Pacaso’s investment opportunity ends September 18.
Paid advertisement for Pacaso’s Regulation A offering. Read the offering circular at invest.pacaso.com. Reserving a ticker symbol is not a guarantee that the company will go public. Listing on the NASDAQ is subject to approvals.
LEARN MORE ABOUT OUR WORK
— Capilli Eternal
Disclaimer:
This newsletter is for informational purposes only and does not substitute professional medical advice. Always consult with a healthcare provider before making any changes to your health regimen.